

Vikas A Gupta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6692708/vikas-a-gupta-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

844
citations

12
h-index

29
g-index

46
ext. papers

1,169
ext. citations

5.6
avg, IF

3.96
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 44 | PI3K γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.. <i>Blood</i> , 2022 , 139, 523-537 | 2.2 | 5 |
| 43 | BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , 2021 , 138, 1624-1624 | 2.2 | |
| 42 | Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1611-1611 | 2.2 | |
| 41 | Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 75.e1-75.e1 | | 0 |
| 40 | Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021 , 137, 3604-3615 | 2.2 | 11 |
| 39 | BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 11-24 | 2.6 | 2 |
| 38 | Oncolytic herpes simplex virus infects myeloma cells and. <i>Molecular Therapy - Oncolytics</i> , 2021 , 20, 519-581 | 1.4 | 3 |
| 37 | Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021 , 96, E68-E71 | 7.1 | 3 |
| 36 | Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 3178-3189 | 12.9 | 1 |
| 35 | Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021 , 2, 600-615 | 7 | 2 |
| 34 | Plasma Cell Neoplasms 2021 , 361-375 | | |
| 33 | Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1228 | 17.4 | 24 |
| 32 | Approaches to Treating Multiple Myeloma, Now and Moving Forward. <i>JCO Oncology Practice</i> , 2020 , 16, 15-16 | 2.3 | 0 |
| 31 | Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020 , 136, 20-21 | 2.2 | |
| 30 | Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 31-32 | 2.2 | |
| 29 | Downregulation of PA28 γ induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 125 | 7 | 3 |
| 28 | Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1928-1937 | 2.2 | 56 |

| | | | |
|----|--|------|----|
| 27 | Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1291-1296 | 10.7 | 20 |
| 26 | Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2019 , 10, 1121 | 8.4 | 49 |
| 25 | Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. <i>Cancer</i> , 2019 , 125, 2991-3000 | 6.4 | 47 |
| 24 | Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019 , 10, 1911 | 17.4 | 53 |
| 23 | Daratumumab in multiple myeloma. <i>Cancer</i> , 2019 , 125, 2364-2382 | 6.4 | 58 |
| 22 | The Role of Proteasome Activator PA28 in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5499-5499 | 2.2 | |
| 21 | Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845. <i>Blood</i> , 2019 , 134, 4413-4413 | 2.2 | |
| 20 | Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019 , 9, 94 | 7 | 59 |
| 19 | Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019 , 125, 416-423 | 6.4 | 22 |
| 18 | Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018 , 132, 3241-3241 | 2.2 | 1 |
| 17 | Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 952-952 | 2.2 | 3 |
| 16 | Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018 , 132, 3294-3294 | 2.2 | 2 |
| 15 | Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 5647-5647 | 2.2 | 2 |
| 14 | The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018 , 132, 5911-5911 | 2.2 | |
| 13 | Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. <i>Blood</i> , 2018 , 132, 405-405 | 2.2 | |
| 12 | Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. <i>Blood</i> , 2017 , 129, 1969-1979 | 2.2 | 57 |
| 11 | Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016 , 17, 769-77 | 4.6 | 11 |
| 10 | Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2013 , 41 | 2.6 | |

| | | | |
|---|---|------|-----|
| 9 | Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1924-1924 | 2.2 | 2 |
| 8 | P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1929-1929 | 2.2 | |
| 7 | Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4446-4446 | 2.2 | 1 |
| 6 | Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1856-1856 | 2.2 | |
| 5 | CD45 2010 , 743-748 | | |
| 4 | B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. <i>Journal of Experimental Medicine</i> , 2008 , 205, 2755-61 | 16.6 | 10 |
| 3 | The juxtamembrane wedge negatively regulates CD45 function in B cells. <i>Immunity</i> , 2005 , 23, 635-47 | 32.3 | 48 |
| 2 | The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. <i>Developmental Cell</i> , 2001 , 1, 63-72 | 10.2 | 288 |
| 1 | Multiple myeloma immunoglobulin λ translocations portend poor prognosis | | 1 |